Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
Official title: A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
594
Start Date
2025-07-16
Completion Date
2028-11
Last Updated
2025-11-18
Healthy Volunteers
No
Interventions
611
611 subcutaneous (SC) injection
Placebo
placebo Q2W, subcutaneous (SC) injection
Locations (4)
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
ZheJiang Provincial People's Hospital
Hangzhou, Zhejiang, China